BioAffinity Technologies Advances CyPath Lung; Stock Surge

(RTTNews) - bioAffinity Technologies Inc. (BIAF) announced that it is advancing the application of its CyPath Lung test to support surveillance of lung cancer patients who have completed curative-intent treatment.

The noninvasive test, which has already demonstrated its ability to detect early-stage lung cancer in clinical trials and practice, is being positioned as a complement to imaging in monitoring for recurrence and new cancers.

Lung cancer recurrence remains a major clinical challenge, with published studies reporting recurrence rates of 20% to 55% for non-small cell lung cancer (NSCLC), depending on stage and treatment.

More than 680,000 Americans are living with a prior lung cancer diagnosis, and another 230,000 are expected to be diagnosed in 2026. Current guidelines recommend surveillance imaging every six months for two years following curative treatment followed by low-dose CT scans.

Physicians note that imaging alone often cannot distinguish between recurrent cancer, new cancer, or benign post-treatment changes such as fibrosis or scarring. CyPath Lung provides a binary result- "unlikely" or "likely malignancy" - that can help guide decisions on whether closer investigation is needed or if continued surveillance is appropriate.

Maria Zannes, President and CEO of bioAffinity Technologies, emphasized that surveillance after treatment has the potential to lead to earlier intervention and improved patient outcomes. She noted that as commercial experience with CyPath Lung grows, the company is exploring how its noninvasive approach can provide value throughout the patient's lung cancer journey.

The advancement of CyPath Lung into post-treatment surveillance highlights bioAffinity's commitment to expanding its diagnostic platform and addressing unmet needs in lung cancer care.

The company implemented a 1-for-30 reverse stock split on September 19, 2025.

BIAF is currently trading at $8.20, up 80.04%